Incannex Healthcare Inc. (IXHL)
After hours:
| Previous close | 1.5900 |
| Open | 1.5950 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.5516 - 1.5950 |
| 52-week range | 0.8000 - 12.6800 |
| Volume | |
| Avg. volume | 26,612 |
| Market cap | 27.964M |
| Beta (5Y monthly) | 2.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1500 |
| Earnings date | 30 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireIncannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
Announced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross proceeds to Incannex Announced positive top-line results from our Phase 2 proof-of-concept clinical trial of PSX-001, known as the PsiGAD1 study, in which synthetic psilocybin in combination with psychotherapy was observed to significantly reduce anxiety scores and to be well tolerated in patients with generalised anxiety disorder (GAD) Commenced dosing in the RePOSA Phase 2/3 clinical trial
- GlobeNewswire
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
Incannex to Receive Funding of Up to $10 Million in Convertible Notes and $50 Million Equity Line of CreditNEW YORK and MELBOURNE, Australia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (the “Company” or “Incannex”), a clinical-stage biopharmaceutical company developing life-changing medicines for people with chronic diseases and significant unmet medical needs, today announced it has entered into an agreement to issue up to $10 million in secured convertible note
- GlobeNewswire
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
Approval from FDA to proceed with 94 patient Phase 2 clinical trial received following review of IND dossier containing information on the clinical trial, as well as safety and quality of the investigational drug product.PsiGAD2, short for Psilocybin for Generalised Anxiety Disorder trial two, follows the PsiGAD1 proof of concept trial, which demonstrated a 12.8 point reduction in the Hamilton Anxiety Rating Sacle (HAM-A) score from baseline in the psilocybin treatment group. NEW YORK and MELBOU
